CN104093419A - Method of preparing broad spectrum vaccine for preventing avian colibacillosis - Google Patents
Method of preparing broad spectrum vaccine for preventing avian colibacillosis Download PDFInfo
- Publication number
- CN104093419A CN104093419A CN201280061063.7A CN201280061063A CN104093419A CN 104093419 A CN104093419 A CN 104093419A CN 201280061063 A CN201280061063 A CN 201280061063A CN 104093419 A CN104093419 A CN 104093419A
- Authority
- CN
- China
- Prior art keywords
- solution
- vaccine
- preparation
- culture
- centrifugation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 8
- 241000271566 Aves Species 0.000 title abstract description 29
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 8
- 101150084075 tsh gene Proteins 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000013612 plasmid Substances 0.000 claims description 28
- 238000001228 spectrum Methods 0.000 claims description 26
- 238000005119 centrifugation Methods 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000012153 distilled water Substances 0.000 claims description 13
- 230000035931 haemagglutination Effects 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 8
- 238000012408 PCR amplification Methods 0.000 claims description 8
- UXUFTKZYJYGMGO-CMCWBKRRSA-N (2s,3s,4r,5r)-5-[6-amino-2-[2-[4-[3-(2-aminoethylamino)-3-oxopropyl]phenyl]ethylamino]purin-9-yl]-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(=O)NCCN)=CC=3)=NC(N)=C2N=C1 UXUFTKZYJYGMGO-CMCWBKRRSA-N 0.000 claims description 7
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 230000035939 shock Effects 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000012137 tryptone Substances 0.000 claims description 6
- 239000011534 wash buffer Substances 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 238000010276 construction Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 239000006137 Luria-Bertani broth Substances 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 238000000151 deposition Methods 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 235000015424 sodium Nutrition 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 230000005713 exacerbation Effects 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 abstract description 23
- 239000000853 adhesive Substances 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 30
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 8
- 230000006798 recombination Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000369 enteropathogenic effect Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 241000283725 Bos Species 0.000 description 2
- 206010016825 Flushing Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 101150058502 Acaca gene Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 206010030306 omphalitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (9)
- Claims1st, a kind of preparation method of the wide spectrum vaccine of prevention birds colibacillosis, it is characterised in that it is carried out according to following steps order:(1) structure of recombinant plasmid1. it is pathogenic with fowl;^ bacillus genes group is template, is expanded using PCR skill trees temperature sensitivity J&^ element tsh genes;2. the temperature sensitive haemagglutination element tsh genes after amplification are inserted on expression vector pEASY- E1, construction of recombinant plasmid vector, then be transformed into 7 1-T1 clone's competent cells;3. the thin & rows culture of competence is cloned to ra/-T1, and extracts plasmid;(2) expression of genePlasmid is transformed into competent cell BL21 (DE3), competent cell BL21 (DE3) is cultivated;(3) preparation of vaccineBy the competent cell BL21 Φ Ε 3 after culture) steam 7 with double]<0D values are released for after 0.800, the final wide language vaccine that prevention birds colibacillosis is made.2nd, the preparation method of the wide spectrum vaccine of prevention birds U bacillosises according to claim 1, it is characterised in that step 1. middle PCR amplification temperature sensitivity J element t sh genes, primer it is as followsSense primer is zxl:5 ,-atgaacagaatttattctcttcgc-3'Anti-sense primer is zx2:5 ,-gaatgaataacgaatattagcgttt- 3,.3rd, the preparation method of the wide spectrum vaccine of the prevention birds colibacillosis according to claim 1 or 1,1. middle PCR amplifications temperature sensitive haemagglutination element tsh gene processes are as follows in step by its special ^:Activation culture APEC bacterial strains, and extract plasmid, the template reacted using the plasmid of extraction as PCR;Will amplification temperature sensitivity>Plain tsh genes, 96 °C of pre-degenerations 5min, 94 °C of denaturation lmin;50 °C of annealing 30 ~ 60s, 72 °C of ^ l ~ 2min, 30 circulations;After 72 °C of extension lOmin, 4 °C of refrigerators are placed in, the temperature sensitive haemagglutination element tsh genes after amplification are produced. 4th, the preparation method of the wide spectrum vaccine of prevention birds colibacillosis according to claim 1, it is characterised in that the tool ^ of step 2. is carried out according to following steps order:Al, PCR is expanded after temperature sensitive haemagglutination element tsh genes, pEASY- E1 carriers and distilled water 25 °C are placed in after mixing, be incubated 20min, form the restructuring shield grain of PCR primer and pEASY-El vector constructions;Bl, exacerbation M " grains flick mixing, 10 ~ 15min of ice bath in 50 Transl- Ι competent cells;After Cl, 42 °C of heat shock 30s, it is immediately placed on ice;Dl, after be added to the LB liquid that temperature is room temperature and support in base, put shaking table into, 37 °C of lower 200rpm are incubated lh, obtain bacterium solution;El, take 200 μ bacterium solutions to be placed on flat board to carry out bed board, overnight incubation produces the Transl-Tl cells containing recombinant plasmid.5th, the preparation method of the wide spectrum vaccine of prevention birds colibacillosis according to claim 4, it is characterised in that:Flat board described in step E1 is to support base with the solid ^^ of LB to be placed in flat board made in training ^, and 40mg/mL ampicillin sodiums are contained wherein in LB culture mediums.The solid ^ of described LB!■, which supports based formulas, to be included:Yeast extract 5g, Tryptone lOg, NaCl 5g, agar l Og, remaining is distilled water, is settled to 1L.6th, the preparation method of the wide spectrum vaccine of prevention birds bacillosis according to claim 4, it is characterised in that the LB Liquid Culture based formulas described in step D1 includes:Yeas t extract 5g, Tryptone lOg, NaCl 5g, remaining is distilled water, is settled to 1L;7th, the preparation method of the wide spectrum vaccine of prevention birds colibacillosis according to claim 1, it is characterised in that the specific peace of step 3. is carried out according to following steps order:A2, monoclonal bacterium colony are in 1. 5mL LB culture mediums, 37 °C of lower 300rpm cultures 18h;B2, W " foster bacterium solution carries out centrifugation and grasps ashamed, and centrifugal force is 10000g, and centrifugation time is lmin, and abandoning supernatant leaves bacterial sediment; C2, into bacterial sediment add 250 Solution I, whirlpool 2min, obtain solution a;D2, the Solution II for adding into solution a 250 y L, rotating centrifugal pipe are gently mixed, and are incubated 3min, are obtained solution b;E2, add 350 Solution III into solution b, mixing is overturned several times immediately, until there is floccule precipitation, obtains solution c;F2, solution c centrifuged into 10min under 13000g, obtain supernatant and white depositions;G2, to 2mL with centrifugal column centrifuge tube in, add 100 equilibrium liquids, 13000g centrifugation 60s, discard efflux;H2, the careful F2 that draws walk obtained supernatant in centrifugal column, and 13000g centrifugation lmin discard efflux;12nd, 500 μ ν HB Buffer, 13000g centrifugation 60s are added, efflux is discarded;J2,700 μ of addition!DNA wash buffer, 13000 g centrifugation 60s, discard efflux;K2, repeat step J2, discard efflux;L2,13000g centrifuge 2min, thoroughly remove liquid, obtain the centrifugal column containing DNA;M2, ^ mouthfuls of the centrifugation containing DNA entered into the centrifuge tube of 1. clean 5mL, add 50 μ Ε Β, be incubated at room temperature 60s, 13000g centrifugation 60s, collect DNA, obtain weight ^ib.8th, the preparation method of the wide spectrum vaccine of prevention birds colibacillosis according to claim 7, it is characterised in that:The DNA wash buffer described in the Solution II described in Solution I, step D2, the Solution III described in step E2, the equilibrium liquid described in step G2, the HB Buffer described in step 12 and step J2 described in described step C2 are the composition in the kit of the OMEGA companies production of Plasmid Mini Kit I D6943-01* models.9th, the preparation method of the wide spectrum vaccine of prevention birds bacillosis according to claim 1, its special tool in step (2) is first as follows:A3, take the BL2 DE3 melted on 50 μ ice baths) competent cell, add in weight grain, gently shake up, 30min is placed in ice bath, obtain being combined with BL21 (DE3) cell of recombinant plasmid on the thin moon; B3, the BL21 of recombinant plasmid (DE3) cells heat shock 45s under 42 °C of water bath conditions will be combined with thin ^, then BL21 (DE3) cell for being transferred to 2min in ice bath, obtaining containing weight grain in cell of quick and stable;The sterile LB culture mediums without antibiotic of 500 L are added in C3, BL21 (DE3) cell into cell containing weight grain, 37 °C, 200rpm culture 2h, the thalline recovered are placed in after mixing;D3, the thalline of absorption different volumes recovery are applied on solid LB media, 37 °C of culture 16h;The bacterium colony grown on E3, culture medium, enters performing PCR identification.10th, the preparation method of the wide language vaccine of prevention birds W bacillosises according to claim 1, it is characterised in that the concrete operations of step (3) are as follows:It is 0. 800 by dilute Dry to the 0D values of the bacterium solution distilled water of fermented and cultured, is come with this as immunovac parenteral solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280061063.7A CN104093419B (en) | 2012-09-24 | 2012-12-10 | The preparation method of the wide spectrum vaccine of prevention birds colibacillosis |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210357304 | 2012-09-24 | ||
CN201210357304.4 | 2012-09-24 | ||
CN2012103573044 | 2012-09-24 | ||
PCT/CN2012/001677 WO2014043838A1 (en) | 2012-09-24 | 2012-12-10 | Method of preparing broad spectrum vaccine for preventing avian colibacillosis |
CN201280061063.7A CN104093419B (en) | 2012-09-24 | 2012-12-10 | The preparation method of the wide spectrum vaccine of prevention birds colibacillosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104093419A true CN104093419A (en) | 2014-10-08 |
CN104093419B CN104093419B (en) | 2016-04-20 |
Family
ID=50340506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280061063.7A Active CN104093419B (en) | 2012-09-24 | 2012-12-10 | The preparation method of the wide spectrum vaccine of prevention birds colibacillosis |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN104093419B (en) |
IN (1) | IN2015DN02393A (en) |
MY (1) | MY178705A (en) |
WO (1) | WO2014043838A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105717297A (en) * | 2016-03-03 | 2016-06-29 | 河北科星药业有限公司 | Avian colibacillosis Tshs antibody enzyme indirect ELISA detection kit, detection method and application |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106987549B (en) * | 2017-04-26 | 2020-08-21 | 河北科星药业有限公司 | Culture medium and corresponding production method of broad-spectrum bacterin for preventing poultry colibacillosis |
CN108096582B (en) * | 2018-01-17 | 2021-04-30 | 河北科星药业有限公司 | Freeze-drying protective agent for live vaccine of avian colibacillosis |
CN113736811B (en) * | 2021-07-30 | 2023-07-18 | 河北科星药业有限公司 | Plasmid for promoting extracellular expression of tshs and yncE genes, construction method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399074B1 (en) * | 1998-07-24 | 2002-06-04 | Megan Health, Inc. | Live attenuated salmonella vaccines to control avian pathogens |
CN101096706B (en) * | 2007-06-29 | 2012-03-28 | 扬州大学 | DNA chip for detecting virulence gene expression abilities of APEC and UPEC and construction method thereof |
CN102580074B (en) * | 2011-01-07 | 2015-07-15 | 北京大北农科技集团股份有限公司 | Riemerella anatipestifer-escherichia coli outer membrane protein bivalent vaccine and preparation method thereof |
-
2012
- 2012-12-10 CN CN201280061063.7A patent/CN104093419B/en active Active
- 2012-12-10 IN IN2393DEN2015 patent/IN2015DN02393A/en unknown
- 2012-12-10 WO PCT/CN2012/001677 patent/WO2014043838A1/en active Application Filing
- 2012-12-10 MY MYPI2015700908A patent/MY178705A/en unknown
Non-Patent Citations (2)
Title |
---|
伊亚莉: "紫花苜蓿几丁质酶Class I基因的克隆、序列分析及其表达", 《中国优秀硕士学位论文全文数据库农业科技辑》 * |
魏宽翠等: "禽致病性大肠埃希菌黏附素研究进展", 《动物医学进展》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105717297A (en) * | 2016-03-03 | 2016-06-29 | 河北科星药业有限公司 | Avian colibacillosis Tshs antibody enzyme indirect ELISA detection kit, detection method and application |
Also Published As
Publication number | Publication date |
---|---|
MY178705A (en) | 2020-10-20 |
IN2015DN02393A (en) | 2015-09-04 |
CN104093419B (en) | 2016-04-20 |
WO2014043838A1 (en) | 2014-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109169702B (en) | Nano RNAi preparation and preparation method and application thereof | |
CN113198011B (en) | Duck adenovirus type 3 strain inactivated vaccine and application thereof | |
CN101381695B (en) | Riemerella anatipestifer blood serum 1 type genetic engineering attenuated strain and construction method thereof | |
CN107653260A (en) | A kind of preparation method and application of Recombinant Lactococcus lactis | |
CN106729694A (en) | A kind of I group of 4 type aviadenovirus DNA vaccination and its application | |
CN104093419A (en) | Method of preparing broad spectrum vaccine for preventing avian colibacillosis | |
CN114774372B (en) | Coxsackie virus A10 type strain and vaccine and application thereof | |
CN104974249B (en) | Riemerellosis Anatipestifer OmpA/MotB truncates recombinant protein, its antibody and preparation method and application | |
CN106520710A (en) | Preparation method and application of live vector vaccine for expressing duck Tembusu virus (DTMUV) prm and E protein recombinant Newcastle disease virus (NDV) | |
CN101979502B (en) | Recombinant brucella expressing VP1 gene of O-type foot-and-mouth disease virus and method for producing vaccines thereof | |
CN103877570B (en) | Rabies live vaccine and the method preparing rabies live oral vaccine | |
CN109568572A (en) | A kind of preparation method and applications of Aeromonas Multivalent DNA Vaccine | |
CN102206257B (en) | Edwardsiella tarda immunogenic protective antigen, and related expression vector, vaccine and application | |
CN109266593A (en) | Based on Ngpiwi protein mediated eggs crack detection gene knock-out bacterial strain and its construction method and application | |
CN104530230A (en) | Duck hepatitis A virus VP1 protein gene and application thereof | |
CN101979503B (en) | Recombinant brucella for expressing Asia type-I foot and mouth disease virus VP1 genes and method for producing vaccines thereof | |
CN102604993B (en) | Immunologic adjuvant-Helicobacter pylori antigen fused protein oral vaccine and preparation method thereof | |
CN106834199A (en) | Pseudomonas aeruginosa pyoS5 gene knockout mutant strains and construction method and application | |
CN106190943A (en) | A kind of dual-gene disappearance Salmonella enteritidis, its construction method and the vaccine containing this dual-gene disappearance Salmonella enteritidis | |
CN105316252A (en) | Five-gene-deleted streptococcus suis serotype 2 strain and application | |
CN104497120B (en) | The application of grouper Clonorchiasis Sinensis TCTP and its encoding gene in terms of anti-fish nervous necrosis virus | |
CN101906166B (en) | Streptococcus recombination subunit vaccine and preparation method | |
CN109247328B (en) | LDH-dsRNA nanocrystallization preparation and preparation method and application thereof | |
CN103589693B (en) | A kind of expression IBDV VP2 and bursa of Fabricius bursin chimeric protein recombinant herpesvirus of turkeys | |
CN107164252A (en) | A kind of RHDV subunit vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201231 Address after: 570145 room 1506, Yusha international, 11-8 Yusha Road, Longhua District, Haikou City, Hainan Province Patentee after: Quanku (Hainan) Intellectual Property Operation Co.,Ltd. Address before: 050200 No.114 Changsheng street, high tech Industrial Development Zone, Luquan City, Shijiazhuang City, Hebei Province Patentee before: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210126 Address after: 050200 No.114 Changsheng street, Luquan Development Zone, Shijiazhuang City, Hebei Province Patentee after: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Address before: 570145 room 1506, Yusha international, 11-8 Yusha Road, Longhua District, Haikou City, Hainan Province Patentee before: Quanku (Hainan) Intellectual Property Operation Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20141008 Assignee: HEBEI GREENLAND ANIMAL PHARMACEUTICAL Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002827 Denomination of invention: Preparation method of broad-spectrum vaccine for preventing avian Escherichia coli disease Granted publication date: 20160420 License type: Common License Record date: 20240314 Application publication date: 20141008 Assignee: Hebei jianjiale duck industry Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002825 Denomination of invention: Preparation method of broad-spectrum vaccine for preventing avian Escherichia coli disease Granted publication date: 20160420 License type: Common License Record date: 20240313 Application publication date: 20141008 Assignee: Shijiazhuang Huifeng Animal Health Products Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002822 Denomination of invention: Preparation method of broad-spectrum vaccine for preventing avian Escherichia coli disease Granted publication date: 20160420 License type: Common License Record date: 20240313 |
|
EE01 | Entry into force of recordation of patent licensing contract |